Tumor volume reduction assessed by planning computed tomography in patients with rectal cancer during preoperative chemoradiation: Impact of residual tumor volume on the prediction of pathologic tumor regression

Jung Ae Lee, Dae-Sik Yang, Won Sup Yoon, Young Je Park, Chul Yong Kim, Hong Young Moon, Sun Il Lee

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Aims and background. To determine whether the residual tumor volume measured using the Eclipse treatment planning system correlates with pathologic tumor regression grade after preoperative chemoradiotherpy for rectal cancer. Materials and methods. The study included 30 patients with rectal cancer who had undergone preoperative chemoradiotherpy followed by surgery from June 2008 to April 2011 at the Korea University Guro Hospital. The tumor volume was measured using the Eclipse treatment planning system in the initial simulation computed tomography and boost planning computed tomography. The correlation between the residual tumor volume in boost planning computed tomography and the pathologic tumor regression grade was analyzed. Tumor regression grade defined in the American Joint Committee on Cancer 7th edition was used. Results. The mean and median residual tumor volume was 57.34% ± 20.37% and 52.35% (range, 18.42%-95.79%), respectively. After surgery, pathologic complete response (tumor regression grade 0) occurred in 4 patients (13.33%), moderate response (tumor regression grade 1) in 18 patients (60%), minimal response (tumor regression grade 2) in 4 patients (13.33%), and poor response (tumor regression grade 3) in 4 patients (13.33%). When residual tumor volume was categorized into two groups (<50% and ≥50%), complete or moderate regression (tumor regression grade 0 or 1) was significantly greater for patients with a residual tumor volume <50% (P <0.05). The mean residual tumor volume of tumor regression grade 0 or 1 was 49.07% ± 18.39% and that of tumor regression grade 2 or 3 was 76.31% ± 16.94% (P <0.05). Conclusions. Residual tumor volume measured using routine boost planning computed tomography during preoperative chemoradiotherpy correlated significantly with pathologic tumor regression grade after surgery. Copyright - Il Pensiero Scientifico Editore.

Original languageEnglish
Pages (from-to)158-162
Number of pages5
JournalTumori
Volume100
Issue number2
DOIs
Publication statusPublished - 2014 Jan 1

Fingerprint

Residual Volume
Residual Neoplasm
Rectal Neoplasms
Tumor Burden
Tomography
Neoplasms
Korea

Keywords

  • Pathologic tumor regression grade
  • Preoperative concurrent chemoradiotherapy
  • Rectal cancer
  • Residual tumor volume

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

@article{d787fff5c6a446e59bcd689ef5f5785b,
title = "Tumor volume reduction assessed by planning computed tomography in patients with rectal cancer during preoperative chemoradiation: Impact of residual tumor volume on the prediction of pathologic tumor regression",
abstract = "Aims and background. To determine whether the residual tumor volume measured using the Eclipse treatment planning system correlates with pathologic tumor regression grade after preoperative chemoradiotherpy for rectal cancer. Materials and methods. The study included 30 patients with rectal cancer who had undergone preoperative chemoradiotherpy followed by surgery from June 2008 to April 2011 at the Korea University Guro Hospital. The tumor volume was measured using the Eclipse treatment planning system in the initial simulation computed tomography and boost planning computed tomography. The correlation between the residual tumor volume in boost planning computed tomography and the pathologic tumor regression grade was analyzed. Tumor regression grade defined in the American Joint Committee on Cancer 7th edition was used. Results. The mean and median residual tumor volume was 57.34{\%} ± 20.37{\%} and 52.35{\%} (range, 18.42{\%}-95.79{\%}), respectively. After surgery, pathologic complete response (tumor regression grade 0) occurred in 4 patients (13.33{\%}), moderate response (tumor regression grade 1) in 18 patients (60{\%}), minimal response (tumor regression grade 2) in 4 patients (13.33{\%}), and poor response (tumor regression grade 3) in 4 patients (13.33{\%}). When residual tumor volume was categorized into two groups (<50{\%} and ≥50{\%}), complete or moderate regression (tumor regression grade 0 or 1) was significantly greater for patients with a residual tumor volume <50{\%} (P <0.05). The mean residual tumor volume of tumor regression grade 0 or 1 was 49.07{\%} ± 18.39{\%} and that of tumor regression grade 2 or 3 was 76.31{\%} ± 16.94{\%} (P <0.05). Conclusions. Residual tumor volume measured using routine boost planning computed tomography during preoperative chemoradiotherpy correlated significantly with pathologic tumor regression grade after surgery. Copyright - Il Pensiero Scientifico Editore.",
keywords = "Pathologic tumor regression grade, Preoperative concurrent chemoradiotherapy, Rectal cancer, Residual tumor volume",
author = "Lee, {Jung Ae} and Dae-Sik Yang and Yoon, {Won Sup} and Park, {Young Je} and Kim, {Chul Yong} and Moon, {Hong Young} and Lee, {Sun Il}",
year = "2014",
month = "1",
day = "1",
doi = "10.1700/1491.16401",
language = "English",
volume = "100",
pages = "158--162",
journal = "Tumori",
issn = "0300-8916",
publisher = "Wichtig Publishing",
number = "2",

}

TY - JOUR

T1 - Tumor volume reduction assessed by planning computed tomography in patients with rectal cancer during preoperative chemoradiation

T2 - Impact of residual tumor volume on the prediction of pathologic tumor regression

AU - Lee, Jung Ae

AU - Yang, Dae-Sik

AU - Yoon, Won Sup

AU - Park, Young Je

AU - Kim, Chul Yong

AU - Moon, Hong Young

AU - Lee, Sun Il

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Aims and background. To determine whether the residual tumor volume measured using the Eclipse treatment planning system correlates with pathologic tumor regression grade after preoperative chemoradiotherpy for rectal cancer. Materials and methods. The study included 30 patients with rectal cancer who had undergone preoperative chemoradiotherpy followed by surgery from June 2008 to April 2011 at the Korea University Guro Hospital. The tumor volume was measured using the Eclipse treatment planning system in the initial simulation computed tomography and boost planning computed tomography. The correlation between the residual tumor volume in boost planning computed tomography and the pathologic tumor regression grade was analyzed. Tumor regression grade defined in the American Joint Committee on Cancer 7th edition was used. Results. The mean and median residual tumor volume was 57.34% ± 20.37% and 52.35% (range, 18.42%-95.79%), respectively. After surgery, pathologic complete response (tumor regression grade 0) occurred in 4 patients (13.33%), moderate response (tumor regression grade 1) in 18 patients (60%), minimal response (tumor regression grade 2) in 4 patients (13.33%), and poor response (tumor regression grade 3) in 4 patients (13.33%). When residual tumor volume was categorized into two groups (<50% and ≥50%), complete or moderate regression (tumor regression grade 0 or 1) was significantly greater for patients with a residual tumor volume <50% (P <0.05). The mean residual tumor volume of tumor regression grade 0 or 1 was 49.07% ± 18.39% and that of tumor regression grade 2 or 3 was 76.31% ± 16.94% (P <0.05). Conclusions. Residual tumor volume measured using routine boost planning computed tomography during preoperative chemoradiotherpy correlated significantly with pathologic tumor regression grade after surgery. Copyright - Il Pensiero Scientifico Editore.

AB - Aims and background. To determine whether the residual tumor volume measured using the Eclipse treatment planning system correlates with pathologic tumor regression grade after preoperative chemoradiotherpy for rectal cancer. Materials and methods. The study included 30 patients with rectal cancer who had undergone preoperative chemoradiotherpy followed by surgery from June 2008 to April 2011 at the Korea University Guro Hospital. The tumor volume was measured using the Eclipse treatment planning system in the initial simulation computed tomography and boost planning computed tomography. The correlation between the residual tumor volume in boost planning computed tomography and the pathologic tumor regression grade was analyzed. Tumor regression grade defined in the American Joint Committee on Cancer 7th edition was used. Results. The mean and median residual tumor volume was 57.34% ± 20.37% and 52.35% (range, 18.42%-95.79%), respectively. After surgery, pathologic complete response (tumor regression grade 0) occurred in 4 patients (13.33%), moderate response (tumor regression grade 1) in 18 patients (60%), minimal response (tumor regression grade 2) in 4 patients (13.33%), and poor response (tumor regression grade 3) in 4 patients (13.33%). When residual tumor volume was categorized into two groups (<50% and ≥50%), complete or moderate regression (tumor regression grade 0 or 1) was significantly greater for patients with a residual tumor volume <50% (P <0.05). The mean residual tumor volume of tumor regression grade 0 or 1 was 49.07% ± 18.39% and that of tumor regression grade 2 or 3 was 76.31% ± 16.94% (P <0.05). Conclusions. Residual tumor volume measured using routine boost planning computed tomography during preoperative chemoradiotherpy correlated significantly with pathologic tumor regression grade after surgery. Copyright - Il Pensiero Scientifico Editore.

KW - Pathologic tumor regression grade

KW - Preoperative concurrent chemoradiotherapy

KW - Rectal cancer

KW - Residual tumor volume

UR - http://www.scopus.com/inward/record.url?scp=84901404859&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901404859&partnerID=8YFLogxK

U2 - 10.1700/1491.16401

DO - 10.1700/1491.16401

M3 - Article

C2 - 24852859

AN - SCOPUS:84901404859

VL - 100

SP - 158

EP - 162

JO - Tumori

JF - Tumori

SN - 0300-8916

IS - 2

ER -